Recombinant Human CD314/NKG2D protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3295

---

Validation Data Gallery

• 

  Purity of Recombinant Human NKG2D was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human NKG2D protein Phe78-Val216 (Accession# P26718-1) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 22914
• Accession: P26718-1
• PredictedSize: 43.3 kDa
• SDS-PAGE: 45-65 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD314, also known as NKG2D or Killer cell lectin-like receptor subfamily K member 1 (KLRK1), is a type II lectin-like transmembrane stimulatory receptor. In humans, it is expressed on NK cells, gamma delta T cells, and CD8+ alpha beta T cells. Various families of cell surface ligands have been identified, including the MICA/MICB and ULBP proteins. CD314 is involved in both innate and adaptive immunities, and the NKG2D/NKG2DL pathway involves multiple effector cell types for controlling tumor progression.

References:

1. T Yabe. et al.(1993) Immunogenetics.37(6):455-60.
2. S Bauer. et al.(1999) Science.285(5428):727-9.
3. Amanda M Jamieson. et al.(2002) Immunity.17(1):19-29
4. Huifang Liu. et al.(2019) Am J Cancer Res. 9(10):2064-2078.